The new chemotherapeutic combination (5-FU, irinotecan, and oxaliplatin) and monoclonal antibodies against the epidermal growth factor receptor prevented the metastasis of CRC and improved the survival of patients compared with what has been observed over the past decades22. This evidence concerns the gene EGFR and colorectal carcinoma.